HK1195907A1 - 取代的 -二氫咪唑並 喹唑啉鹽 - Google Patents

取代的 -二氫咪唑並 喹唑啉鹽

Info

Publication number
HK1195907A1
HK1195907A1 HK14109333.1A HK14109333A HK1195907A1 HK 1195907 A1 HK1195907 A1 HK 1195907A1 HK 14109333 A HK14109333 A HK 14109333A HK 1195907 A1 HK1195907 A1 HK 1195907A1
Authority
HK
Hong Kong
Prior art keywords
dihydroimidazo
substituted
quinazoline
salts
quinazoline salts
Prior art date
Application number
HK14109333.1A
Other languages
English (en)
Inventor
．彼得斯
．米利策爾
．米勒
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43984137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1195907(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of HK1195907A1 publication Critical patent/HK1195907A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
HK14109333.1A 2011-04-05 2014-09-16 取代的 -二氫咪唑並 喹唑啉鹽 HK1195907A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11161111A EP2508525A1 (en) 2011-04-05 2011-04-05 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
PCT/EP2012/055600 WO2012136553A1 (en) 2011-04-05 2012-03-29 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Publications (1)

Publication Number Publication Date
HK1195907A1 true HK1195907A1 (zh) 2014-11-28

Family

ID=43984137

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14109333.1A HK1195907A1 (zh) 2011-04-05 2014-09-16 取代的 -二氫咪唑並 喹唑啉鹽

Country Status (42)

Country Link
US (2) US10383876B2 (zh)
EP (2) EP2508525A1 (zh)
JP (2) JP5763834B2 (zh)
KR (1) KR101937501B1 (zh)
CN (1) CN103649091B (zh)
AP (1) AP3709A (zh)
AR (1) AR085718A1 (zh)
AU (1) AU2012238891B2 (zh)
BR (1) BR112013025549A2 (zh)
CA (1) CA2832123C (zh)
CL (1) CL2013002870A1 (zh)
CO (1) CO6781534A2 (zh)
CR (1) CR20130511A (zh)
CU (1) CU24208B1 (zh)
CY (1) CY1116231T1 (zh)
DK (1) DK2694508T3 (zh)
DO (1) DOP2013000223A (zh)
EA (1) EA023646B1 (zh)
EC (1) ECSP13013006A (zh)
ES (1) ES2529653T3 (zh)
GT (1) GT201300234A (zh)
HK (1) HK1195907A1 (zh)
HR (1) HRP20150138T1 (zh)
IL (1) IL228561A (zh)
JO (1) JO2958B1 (zh)
MA (1) MA35014B1 (zh)
ME (1) ME02021B (zh)
MX (1) MX336057B (zh)
MY (1) MY169452A (zh)
PE (1) PE20141038A1 (zh)
PL (1) PL2694508T3 (zh)
PT (1) PT2694508E (zh)
RS (1) RS53811B1 (zh)
SG (1) SG193595A1 (zh)
SI (1) SI2694508T1 (zh)
SM (1) SMT201500037B (zh)
TN (1) TN2013000401A1 (zh)
TW (2) TWI592158B (zh)
UA (1) UA111604C2 (zh)
UY (1) UY33985A (zh)
WO (1) WO2012136553A1 (zh)
ZA (1) ZA201307105B (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
UA119537C2 (uk) 2013-04-08 2019-07-10 Байєр Фарма Акцієнгезелльшафт ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
CA2915311A1 (en) 2013-06-14 2014-12-18 Bayer Pharma Aktiengesellschaft Anti-tweakr antibodies and uses thereof
CN103694319B (zh) * 2013-12-20 2018-02-27 深圳翰宇药业股份有限公司 一种布舍瑞林的纯化方法
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
AU2016231259A1 (en) 2015-03-09 2017-09-21 Bayer Healthcare Pharmaceuticals Inc. Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
KR20170128567A (ko) 2015-03-23 2017-11-22 바이엘 파마 악티엔게젤샤프트 항-ceacam6 항체 및 그의 용도
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
TN2018000272A1 (en) 2016-02-01 2020-01-16 Bayer Pharma AG Copanlisib biomarkers
EP3411497A1 (en) 2016-02-01 2018-12-12 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
DK3423105T3 (da) 2016-03-02 2021-07-26 Eisai R&D Man Co Ltd Antistof-lægemiddelkonjugater på basis af eribulin og fremgangsmåder til anvendelse heraf
CA3016584A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
CA3037626A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2018112176A1 (en) 2016-12-14 2018-06-21 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
US11684672B2 (en) 2017-02-24 2023-06-27 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-PD-1 antibody
WO2019002068A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
WO2019048527A1 (en) * 2017-09-08 2019-03-14 Bayer Pharma Aktiengesellschaft COPANLISIB FORMULATIONS
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
US20210369724A1 (en) * 2018-10-16 2021-12-02 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
US20210395186A1 (en) * 2018-10-17 2021-12-23 Sandoz Ag Co-Crystals Comprising Levothyroxine And A Dicarboxylic Acid
JP7195027B2 (ja) * 2018-12-27 2022-12-23 ホロスメディック 新規の化合物およびこれを含む抗癌活性増進用薬学組成物
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605550A5 (zh) 1972-06-08 1978-09-29 Research Corp
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TW225528B (zh) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
AU2003293310B2 (en) 2002-09-30 2010-04-01 Bayer Intellectual Property Gmbh Fused azole-pyrimidine derivatives
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8859572B2 (en) 2008-01-14 2014-10-14 Bayer Intellectual Property Gmbh Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
SG184550A1 (en) 2010-04-16 2012-11-29 Bayer Ip Gmbh Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
UA119537C2 (uk) * 2013-04-08 2019-07-10 Байєр Фарма Акцієнгезелльшафт ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
CN105934256B (zh) 2013-12-03 2019-12-27 拜耳制药股份公司 Pi3k-抑制剂的组合产品
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
AU2016231259A1 (en) 2015-03-09 2017-09-21 Bayer Healthcare Pharmaceuticals Inc. Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Also Published As

Publication number Publication date
CY1116231T1 (el) 2017-02-08
PT2694508E (pt) 2015-02-10
JP2014510119A (ja) 2014-04-24
HRP20150138T1 (hr) 2015-05-08
AP3709A (en) 2016-05-31
SG193595A1 (en) 2013-10-30
DK2694508T3 (en) 2015-02-16
CU20130133A7 (es) 2014-01-29
ES2529653T3 (es) 2015-02-24
BR112013025549A2 (pt) 2016-12-27
JO2958B1 (en) 2016-03-15
UA111604C2 (uk) 2016-05-25
TW201637656A (zh) 2016-11-01
AP2013007219A0 (en) 2013-10-31
US20140072529A1 (en) 2014-03-13
EP2508525A1 (en) 2012-10-10
AU2012238891B2 (en) 2016-12-01
KR20140021637A (ko) 2014-02-20
IL228561A0 (en) 2013-12-31
ME02021B (me) 2015-05-20
MX336057B (es) 2016-01-07
AU2012238891A1 (en) 2013-10-24
EP2694508A1 (en) 2014-02-12
WO2012136553A1 (en) 2012-10-11
JP5763834B2 (ja) 2015-08-12
JP5826961B2 (ja) 2015-12-02
CR20130511A (es) 2013-12-04
RS53811B1 (en) 2015-06-30
EP2694508B1 (en) 2014-11-19
CN103649091B (zh) 2016-06-22
DOP2013000223A (es) 2013-11-15
EA201391470A1 (ru) 2014-03-31
CO6781534A2 (es) 2013-10-31
CU24208B1 (es) 2016-11-29
JP2015164936A (ja) 2015-09-17
US9636344B2 (en) 2017-05-02
PL2694508T3 (pl) 2015-04-30
ZA201307105B (en) 2014-11-26
KR101937501B1 (ko) 2019-01-10
CL2013002870A1 (es) 2014-06-20
CA2832123C (en) 2018-09-11
SI2694508T1 (sl) 2015-03-31
UY33985A (es) 2012-10-31
US10383876B2 (en) 2019-08-20
IL228561A (en) 2015-10-29
TN2013000401A1 (en) 2015-03-30
MA35014B1 (fr) 2014-04-03
EA023646B1 (ru) 2016-06-30
MY169452A (en) 2019-04-11
PE20141038A1 (es) 2014-09-05
MX2013011583A (es) 2013-12-16
GT201300234A (es) 2015-01-16
CN103649091A (zh) 2014-03-19
ECSP13013006A (es) 2013-12-31
US20160193219A1 (en) 2016-07-07
NZ616198A (en) 2015-09-25
TW201249847A (en) 2012-12-16
AR085718A1 (es) 2013-10-23
CA2832123A1 (en) 2012-10-11
TWI592158B (zh) 2017-07-21
SMT201500037B (it) 2015-05-05
TWI549954B (zh) 2016-09-21

Similar Documents

Publication Publication Date Title
HK1195907A1 (zh) 取代的 -二氫咪唑並 喹唑啉鹽
IL231903A0 (en) Imidazo[1, 2,c] pyrimidines are converted at positions 5 and 7
HK1220121A1 (zh) 取代的 -二氫咪唑並 喹唑啉治療淋巴瘤的用途
AP3751A (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
HK1182937A1 (zh) 含取代的 -二氫咪唑並 喹唑啉的組合
HK1192248A1 (zh) 用作激酶抑制劑的吡唑并 嘧啶
EP2945632A4 (en) HETEROBICCLOSUBSTITUTED [1,2,4] TRIAZOLO [1,5-C] CHINAZOLINE-5-AMINE COMPOUNDS WITH A2A ANTAGONISTIC PROPERTIES
EP2718182A4 (en) AILETTE CLOSED IN LOOP ON THE END OF THE WING
EP2758483A4 (en) AGENTS GELING PYROMELLITAMIDES
HK1190712A1 (zh) 芳基氨基醇取代的 -二氫咪唑並 喹啉
EP2796442A4 (en) ANALOG COMPOUND FROM A CAJANINE STRUCTURE, MANUFACTURING METHOD AND USE THEREOF
EP2699091A4 (en) 2 ', 6'-dioxo-3'-deutero-PIPERIDIN-3-YL-isoindoline COMPOUNDS
SI2497744T1 (sl) Orodje za zapiranje
EP2661536A4 (en) Low equivalent circulation density setting tool
EP2739627A4 (en) 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2
IL229993A (en) 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2
HK1198586A1 (zh) -二氟甲基- -二氫- 噁嗪- -胺衍生物
EP2707055A4 (en) REDUCTION OF SOLUBLE UROKINASE RECEPTOR IN THE CIRCULATION
EP2671878A4 (en) SUBSTITUTED N-PENTANAMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF
PL2460684T3 (pl) Obrotowy fotel
IL212512A (en) Stirring cup
AU2011902183A0 (en) Construction Management Methods 2
AU2011902963A0 (en) Attractants for use in Resistance Management
GB201119668D0 (en) Intelligent durable pdc cutter
CO6811852A2 (es) Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas